Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study

Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study

Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID...

Full description

Bibliographic Details
Main Authors: Maria Albanese, Giulia Marrone, Agostino Paolino, Manuela Di Lauro, Francesca Di Daniele, Carlo Chiaramonte, Cartesio D’Agostini, Annalisa Romani, Alessandro Cavaliere, Cristina Guerriero, Andrea Magrini, Nicola Biagio Mercuri, Nicola Di Daniele, Annalisa Noce
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceuticals
Subjects:
SARS-CoV-2
COVID-19
um-PEA
oral food supplement
cytokines storm
oxidative stress
Online Access:https://www.mdpi.com/1424-8247/15/2/253

Internet

https://www.mdpi.com/1424-8247/15/2/253

Similar Items